Skip to Content

Power Drugs

Problems with mitochondria – cells’ tiny energy-producing units – can cause illnesses as diverse as cancer and Parkinson’s disease. Volkmar Weissig, a pharmaceutical scientist at Northeastern University, says he’s devised the first drug delivery system that can shuttle a drug through a cell to target its mitochondria. Weissig coats drugs in a common antibacterial compound; the positively charged coating is attracted to the mitochondria, which are the most negatively charged parts of the cell. In a recent experiment with mice, Weissig found that tumors treated with the coated version of the cancer drug Taxol grew only half as much as those treated with the uncoated drug. Weissig says he could also use the approach to shuttle DNA to the mitochondria, a possible basis for gene therapy to correct mutations in mitochondrial DNA – which have been implicated in neurological diseases such as Parkinson’s and Alzheimer’s. A Boston startup company, MitoVec, plans to couple Weissig’s technology with several existing cancer drugs and begin testing it in humans in two to three years.

Keep Reading

Most Popular

10 Breakthrough Technologies 2024

Every year, we look for promising technologies poised to have a real impact on the world. Here are the advances that we think matter most right now.

Scientists are finding signals of long covid in blood. They could lead to new treatments.

Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests.

AI for everything: 10 Breakthrough Technologies 2024

Generative AI tools like ChatGPT reached mass adoption in record time, and reset the course of an entire industry.

What’s next for AI in 2024

Our writers look at the four hot trends to watch out for this year

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.